Friday, July 10, 2026

Drug profile · INN

delamanid

delamanid (DELTYBA) is a mycobacterium tuberculosis h37rv inhibitor.

EMA: approved PMDA: approved Antiinfectives for systemic use (J04) J04AK06
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — delamanid
Class
Antiinfectives for systemic use (J04)
Route
Patents
0
Programs
5
Data quality
0.83

Quick answer

delamanid (DELTYBA) is a mycobacterium tuberculosis h37rv inhibitor.

Key facts

INN delamanid
Brand DELTYBA
Mechanism Mycobacterium tuberculosis H37Rv inhibitor
Target Mycobacterium tuberculosis H37Rv
Therapeutic class Antiinfectives for systemic use (J04)
ATC code J04AK06

Mechanism of action

Mycobacterium tuberculosis H37Rv inhibitor

Primary target: Mycobacterium tuberculosis H37Rv

Approval history

Authority Status Date
EMA approved
PMDA approved

Pipeline programs

  1. Delamanid + OBR Phase 3 · Otsuka Beijing Research · Multidrug-resistant Tuberculosis
  2. Delamanid Phase 2 · Otsuka Beijing Research · Multidrug Resistant Tuberculosis
  3. Delamanid Phase 2 · Otsuka Beijing Research · Tuberculosis, Multidrug-Resistant
  4. Gates MRI-TBD06-201 Phase 2 · BRIGHT MINDS BIOSCIENCES · Pulmonary Tuberculosis
  5. 100 mg Delamanid Phase 1 · Otsuka Beijing Research · Multidrug Resistant Tuberculosis

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is delamanid?

delamanid (DELTYBA) is a mycobacterium tuberculosis h37rv inhibitor.

What is the brand name for delamanid?

DELTYBA is a marketed brand name for delamanid. Check FDA Drugs@FDA for the current US label holder and prescribing information.